Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Arzerra (ofatumumab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

GSK, Genmab, Novartis

Drug class:

CD20 inhibitor

Related drugs:

‹

SIBP-02 (rituximab biosimilar) (0)

TG20 (rituximab biosimilar) (0)

rituximab (174)

obinutuzumab (68)

epcoritamab-bysp (11)

ublituximab-xiiy (7)

rituximab-pvvr (6)

rituximab-abbs (6)

rituximab/hyaluronidase (5)

Rixathon (rituximab biosimilar) (4)

ibritumomab tiuxetan (3)

mosunetuzumab-axgb (2)

rituximab-arrx (2)

glofitamab-gxbm (1)

TQB2303 (rituximab biosimilar) (1)

odronextamab (1)

Ritucad (rituximab biosimilar) (1)

AcellBia (rituximab biosimilar) (0)

zuberitamab (0)

Avetux (rituximab biosimilar) (0)

BI 695500 (rituximab biosimilar) (0)

CIMAbior (rituximab biosimilar) (0)

DI Leu16 IL-2 (0)

GB241 (rituximab biosimilar) (0)

Halpryza (rituximab biosimilar) (0)

Hanlikon (rituximab biosimilar) (0)

Reditux (rituximab biosimilar) (0)

JHL1101 (rituximab biosimilar) (0)

Kikuzubam (rituximab biosimilar) (0)

MK-8808 (rituximab biosimilar) (0)

MabionCD20 (rituximab biosimilar) (0)

Mabtas (rituximab biosimilar) (0)

Novex (rituximab biosimilar) (0)

ocrelizumab (0)

Retuxira (rituximab biosimilar) (0)

SAIT101 (rituximab biosimilar) (0)

SIBP-02 (rituximab biosimilar) (0)

TG20 (rituximab biosimilar) (0)

›

No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ofatumumab Sensitive: A1 - Approval ofatumumab Sensitive : A1	ofatumumab Sensitive: A1 - Approval ofatumumab Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	ofatumumab Sensitive: A2 - Guideline ofatumumab Sensitive : A2	ofatumumab Sensitive: A2 - Guideline ofatumumab Sensitive : A2
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B
CD20 positive	B Acute Lymphoblastic Leukemia	CD20 positive	B Acute Lymphoblastic Leukemia	ofatumumab Sensitive: C3 – Early Trials ofatumumab Sensitive : C3	ofatumumab Sensitive: C3 – Early Trials ofatumumab Sensitive : C3